EMA — authorised 8 February 2021
- Marketing authorisation holder: ASTRAZENECA AB
- Status: approved
🇪🇺 Lumoxiti in European Union
EMA authorised Lumoxiti on 8 February 2021
Marketing authorisation
Lumoxiti in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Lumoxiti approved in European Union?
Yes. EMA authorised it on 8 February 2021.
Who is the marketing authorisation holder for Lumoxiti in European Union?
ASTRAZENECA AB holds the EU marketing authorisation.